The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients von Treon, Steven P., Castillo, Jorge J., Skarbnik, Alan P., Soumerai, Jacob D., Ghobrial, Irene M., Guerrera, Maria Luisa, Meid, Kirsten, Yang, Guang

Volltext

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia von Treon, Steven P, Tripsas, Christina K, Meid, Kirsten, Warren, Diane, Varma, Gaurav, Green, Rebecca, Argyropoulos, Kimon V, Yang, Guang, Cao, Yang, Xu, Lian, Patterson, Christopher J, Rodig, Scott, Zehnder, James L, Aster, Jon C, Harris, Nancy Lee, Kanan, Sandra, Ghobrial, Irene, Castillo, Jorge J, Laubach, Jacob P, Hunter, Zachary R, Salman, Zeena, Li, Jianling, Cheng, Mei, Clow, Fong, Graef, Thorsten, Palomba, M. Lia, Advani, Ranjana H

Volltext

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia von Castillo, Jorge J, Meid, Kirsten, Gustine, Joshua N, Dubeau, Toni, Severns, Patricia, Hunter, Zachary R, Yang, Guang, Xu, Lian, Treon, Steven P

Volltext

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies von Treon, Steven P, Xu, Lian, Guerrera, Maria Luisa, Jimenez, Cristina, Hunter, Zachary R, Liu, Xia, Demos, Maria, Gustine, Joshua, Chan, Gloria, Munshi, Manit, Tsakmaklis, Nicholas, Chen, Jiaji G, Kofides, Amanda, Sklavenitis-Pistofidis, Romanos, Bustoros, Mark, Keezer, Andrew, Meid, Kirsten, Patterson, Christopher J, Sacco, Antonio, Roccaro, Aldo, Branagan, Andrew R, Yang, Guang, Ghobrial, Irene M, Castillo, Jorge J

Volltext

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia von Castillo, Jorge J., Meid, Kirsten, Gustine, Joshua N., Leventoff, Carly, White, Timothy, Flynn, Catherine A., Sarosiek, Shayna, Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Branagan, Andrew R., O’Donnell, Elizabeth, Raje, Noopur, Yee, Andrew J., Patterson, Christopher J., Hunter, Zachary R., Treon, Steven P.

Volltext

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia von Castillo, Jorge J, Gustine, Joshua N, Meid, Kirsten, Dubeau, Toni, Severns, Patricia, Treon, Steven P

Volltext

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound von Gustine, Joshua N., Meid, Kirsten, Dubeau, Toni, Severns, Patricia, Hunter, Zachary R., Guang, Yang, Xu, Lian, Treon, Steven P., Castillo, Jorge J.

Volltext

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival von Treon, Steven P., Gustine, Joshua, Xu, Lian, Manning, Robert J., Tsakmaklis, Nicholas, Demos, Maria, Meid, Kirsten, Guerrera, Maria L., Munshi, Manit, Chan, Gloria, Chen, Jiaji, Kofides, Amanda, Patterson, Christopher J., Yang, Guang, Liu, Xia, Severns, Patricia, Dubeau, Toni, Hunter, Zachary R., Castillo, Jorge J.

Volltext

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes von Vos, Josephine M., Gustine, Joshua, Rennke, Helmut G., Hunter, Zachary, Manning, Robert J., Dubeau, Toni E., Meid, Kirsten, Minnema, Monique C., Kersten, Marie‐Jose, Treon, Steven P., Castillo, Jorge J.

Volltext

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy von Gustine, Joshua N, Sarosiek, Shayna, Flynn, Catherine A, Meid, Kirsten, Leventoff, Carly, White, Timothy, Guerrera, Maria Luisa, Xu, Lian, Kofides, Amanda, Tsakmaklis, Nicholas, Munshi, Manit, Demos, Maria, Patterson, Christopher J, Liu, Xia, Yang, Guang, Hunter, Zachary R, Branagan, Andrew R, Treon, Steven P, Castillo, Jorge J

Volltext

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214) von Treon, Steven P, Meid, Kirsten, Tripsas, Christina, Heffner, Leonard T, Eradat, Herbert, Badros, Ashraf Z, Xu, Lian, Hunter, Zachary R, Yang, Guang, Patterson, Christopher J, Gustine, Joshua, Castillo, Jorge J, Matous, Jeffrey, Ghobrial, Irene M

Volltext

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia von Castillo, Jorge J, Gustine, Joshua N, Meid, Kirsten, Dubeau, Toni E, Xu, Lian, Yang, Guang, Hunter, Zachary R, Advani, Ranjana, Palomba, Lia, Treon, Steven P

Volltext

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas von Munshi, Manit, Liu, Xia, Chen, Jiaji G., Xu, Lian, Tsakmaklis, Nickolas, Demos, Maria G., Kofides, Amanda, Guerrera, Maria Luisa, Jimenez, Cristina, Chan, Gloria G., Hunter, Zachary R., Palomba, M. Lia, Argyropoulos, Kimon V., Meid, Kirsten, Keezer, Andrew, Gustine, Joshua, Dubeau, Toni, Castillo, Jorge J., Patterson, Christopher J., Wang, Jinhua, Buhrlage, Sara J., Gray, Nathanael S., Treon, Steven P., Yang, Guang

Volltext

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib von Vos, Josephine M, Tsakmaklis, Nickolas, Patterson, Christopher J, Meid, Kirsten, Castillo, Jorge J, Brodsky, Philip, Ganz, Tomas, Pals, Steven T, Kersten, Marie José, Xu, Lian, Yang, Guang, Treon, Steven P, Hunter, Zachary R

Volltext

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib von Castillo, Jorge J., Sarosiek, Shayna, Flynn, Catherine A., Leventoff, Carly, Little, Megan, White, Timothy, Meid, Kirsten, Treon, Steven P.

Volltext

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas von Liu, Xia, Chen, Jiaji G., Munshi, Manit, Hunter, Zachary R., Xu, Lian, Kofides, Amanda, Tsakmaklis, Nickolas, Demos, Maria G., Guerrera, Maria Luisa, Chan, Gloria G., Jimenez, Cristina, Patterson, Christopher J., Meid, Kirsten, Keezer, Andrew, Castillo, Jorge J., Treon, Steven P., Yang, Guang

Volltext

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials von Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.

Volltext

Diagnostic Next‐generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia von Kofides, Amanda, Hunter, Zachary R., Xu, Lian, Tsakmaklis, Nicholas, Demos, Maria G., Munshi, Manit, Liu, Xia, Guerrera, Maria Luisa, Leventoff, Carly R., White, Timothy P., Flynn, Catherine A., Meid, Kirsten, Patterson, Christopher J., Yang, Guang, Branagan, Andrew R., Sarosiek, Shayna, Castillo, Jorge J., Treon, Steven P., Gustine, Joshua N.

Volltext

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia von Treon, Steven P, Meid, Kirsten, Gustine, Joshua, Yang, Guang, Xu, Lian, Liu, Xia, Patterson, Christopher J, Hunter, Zachary R, Branagan, Andrew R, Laubach, Jacob P, Ghobrial, Irene M, Palomba, M Lia, Advani, Ranjana, Castillo, Jorge J

Volltext

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia von Gustine, Joshua N, Xu, Lian, Tsakmaklis, Nicholas, Demos, Maria G, Kofides, Amanda, Chen, Jiaji G, Liu, Xia, Munshi, Manit, Guerrera, Maria Luisa, Chan, Gloria G, Patterson, Christopher J, Keezer, Andrew, Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R, Treon, Steven P, Castillo, Jorge J

Volltext